Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

• Status: Completed
• Trial end date: 2017-02-07
• Target enrollment: 0
• Participant gender: All

Summary

The primary objectives are to determine the progression-free survival (PFS) and to evaluate safety of the trastuzumab, bevacizumab and docetaxel regimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bhuvaneswari Ramaswamy
• Collaborators: Case Comprehensive Cancer Center; Genentech, Inc.; University of Pittsburgh
• Treatments: Bevacizumab; Docetaxel; Trastuzumab

Criteria

Inclusion Criteria:

• Histologically confirmed breast cancer with evidence of metastatic disease

• HER2 3+ or FISH (fluorescent in situ hybridization)+

• Age ≥ 18 years

• No prior trastuzumab, except as given in the adjuvant or neoadjuvant setting.

• No prior chemotherapy in the metastatic setting.

Exclusion Criteria:

• CNS (central nervous system) metastases

• Prior radiation therapy within the last 4 weeks

• Pregnant (positive pregnancy test) or lactating women

• Major surgical procedure, open biopsy, non-healing wounds, or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study

• Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study.